

COPY FOR IB

PATENT COOPERATION TREATY  
PCT

REC'D 16 DEC 2004

WIPO

PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT  
(PCT Article 36 and Rule 70)


Applicant's or agent's file reference 2002OPA2714	FOR FURTHER ACTION	See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)
International application No. <b>PCT/KR2003/000544</b>	International filing date (day/month/year) <b>20 MARCH 2003 (20.03.2003)</b>	Priority date (day/month/year) <b>16 JULY 2002 (16.07.2002)</b>
International Patent Classification (IPC) or national classification and IPC <b>IPC7 C07K 16/18</b>		
Applicant <b>EYEGENE INC. et al</b>		

BEST AVAILABLE COPY

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.
2. This REPORT consists of a total of 4 sheets, including this cover sheet.
 

This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of 1 sheets.
3. This report contains indications relating to the following items:
  - I  Basis of the report
  - II  Priority
  - III  Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
  - IV  Lack of unity of invention
  - V  Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
  - VI  Certain documents cited
  - VII  Certain defects in the international application
  - VIII  Certain observations on the international application

Date of submission of the demand <b>16 FEBRUARY 2004 (16.02.2004)</b>	Date of completion of this report <b>11 NOVEMBER 2004 (11.11.2004)</b>
Name and mailing address of the IPEA/KR  Korean Intellectual Property Office 920 Dunsan-dong, Seo-gu, Daejeon 302-701, Republic of Korea	Authorized officer <b>LEE, Yoon Won</b> Telephone No. <b>82-42-481-5852</b>
Facsimile No. <b>82-42-472-7140</b>	

## INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/KR2003/000544

## I. Basis of the report

1. With regard to the elements of the international application:<sup>\*</sup> the international application as originally filed the description:  
pages 1-11 13 \_\_\_\_\_, as originally filed  
pages \_\_\_\_\_, filed with the demand  
pages \_\_\_\_\_, filed with the letter of \_\_\_\_\_ the claims:  
pages \_\_\_\_\_, as originally filed  
pages \_\_\_\_\_, as amended (together with any statement) under Article 19  
pages \_\_\_\_\_, filed with the demand  
pages 12 \_\_\_\_\_, filed with the letter of 04/11/2004 the drawings:  
pages 1/5-5/5 \_\_\_\_\_, as originally filed  
pages \_\_\_\_\_, filed with the demand  
pages \_\_\_\_\_, filed with the letter of \_\_\_\_\_ the sequence listing part of the description:  
pages 1-5 \_\_\_\_\_, as originally filed  
pages \_\_\_\_\_, filed with the demand  
pages \_\_\_\_\_, filed with the letter of \_\_\_\_\_2. With regard to the language, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.  
These elements were available or furnished to this Authority in the following language English which is the language of a translation furnished for the purposes of international search (under Rule 23.1(b)). the language of publication of the international application (under Rule 48.3(b)). the language of the translation furnished for the purposes of international preliminary examination (under Rules 55.2 and/or 55.3).

## 3. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

 contained in the international application in written form. filed together with the international application in computer readable form. furnished subsequently to this Authority in written form. furnished subsequently to this Authority in computer readable form The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished. The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.4.  The amendments have resulted in the cancellation of: the description, pages \_\_\_\_\_ the claims, Nos. 3-5, 7 \_\_\_\_\_ the drawings, sheets \_\_\_\_\_5.  This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).<sup>\*\*</sup>

\* Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this opinion as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17).

\*\* Any replacement sheet containing such amendments must be referred to under item I and annexed to this report.

**INTERNATIONAL PRELIMINARY EXAMINATION**

International application No.  
PCT/KR2003/000544

**III. Non-establishment of opinion with regard to novelty, inventive step and industrial applicability**

1. The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non obvious), or to be industrially applicable have not been examined in respect of:

- the entire international application,  
 claims Nos. 6, 8-10

because:

- the said international application, or the said claims Nos. 6, 8-10 relate to the following subject matter which does not require an international preliminary examination (*specify*):  
The subject-matter of claims 6, 8-10 does not require an international preliminary examination with respect to industrial applicability as it is directed to a diagnostic method practiced on the human or animal body (Article 34(4)(a)(i), Rule 67.1(iv)).

- the description, claims or drawings (*indicate particular elements below*) or said claims Nos. \_\_\_\_\_ are so unclear that no meaningful opinion could be formed (*specify*):

- the claims, or said claims Nos. \_\_\_\_\_ are so inadequately supported by the description that no meaningful opinion could be formed.  
 no international search report has been established for said claims Nos. \_\_\_\_\_

2. A meaningful international preliminary examination cannot be carried out due to the failure of the nucleotide and/or amino acid sequence listing to comply with the standard provided for in Annex C of the Administrative Instructions:

- the written form has not been furnished or does not comply with the standard.  
 the computer readable form has not been furnished or does not comply with the standard.

## INTERNATIONAL PRELIMINARY EXAMINATION

International application No.

PCT/KR2003/000544

**V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement****1. Statement**

Novelty (N)	Claims _____	YES
	Claims 1-2 _____	NO
Inventive step (IS)	Claims _____	YES
	Claims 1-2 _____	NO
Industrial applicability (IA)	Claims 1-2 _____	YES
	Claims _____	NO

**2. Citations and explanations (Rule 70.7)**

Reference is made to the following documents:

D1: Stolwijk, T. R. et al. "Analysis of tear fluid proteins in insulin-dependent diabetes mellitus" In:Acta Ophthalmologica, 1994, Vol.72(3), pp.357-362

D2:Peebles, R. S. Jr. et al. "IgA, IgG and IgM quantification in bronchoalveolar lavage fluids from allergic rhinitics, allergic asthmatics, and normal subjects by monoclonal antibody-based immunoenzymetric assays" In:J. Immunol. Methods, 1995, Vol.179, pp.77-86

**1. Novelty and Inventive Step**

The present invention relates to the use of IgA polypeptide for diagnosing diabetic retinopathy among diabetic mellitus(DM) patients. The subject matter of the present invention is that the value of IgA in diabetic retinopathy patients is lower than that of IgA in DM patients without retinopathy.

D1 is considered to represent the closest prior art and discloses a statistical analysis of the protein composition in tear fluids from DM patients without retinopathy, DM patients with proliferative retinopathy and healthy controls. Secretory immunoglobulin A (sIgA), lactoferrin, lysozyme and tear specific pre-albumin are analyzed using HPLC and SDS-PAGE. The result teaches that in patients without retinopathy the sIgA concentration is increased compared with that of healthy controls; the level of sIgA is decreased below the level of healthy control. D2 discloses the role of sIgA in various atopic diseases.

The subject matters of the present invention and D1 are the same in that diabetic retinopathy is related to the decreased level of IgA. The person skilled in the art would easily suggest the use of IgA for diagnosing diabetic retinopathy from D1. Thus, the present invention does not satisfy the criteria set forth in Article 33(2) and (3) PCT because the subject matter of claims 1, 2 is not novel in respect of the prior art as defined in the regulations (Rule 64(1)-(3) PCT) and/or does not involve an inventive step (Rule 65(1)(2) PCT).

**2. Industrial Applicability**

Claims 1-2 are considered to be industrially applicable under PCT Article 33(4).

REPLACED BY  
ART 34 AMDT

[What is Claimed is]

1. An Immunoglobulin A protein and an analogous protein or a protein fragment thereof described in SEQ ID NO:1 wherein the protein is effective for diagnosing diabetic retinopathy.
2. The protein fragment according to claim 1, wherein the protein fragment comprises a peptide sequence described in SEQ ID NO:2.
3. An antibody specifically binding the protein of claim 1 or 2.
4. A kit for diagnosing diabetic retinopathy comprising the antibody of claim 3.
5. The kit according to claim 4, further comprising enzyme peroxidase, alkaline phosphatase or biotin conjugated-anti-Immunoglobulin A antibody.
6. A method for diagnosing diabetic retinopathy, comprising:
  - a) treating the antibody of claim 2 with a blood sample and an peroxidase, alkaline phosphatase or biotin conjugated-anti-Immunoglobulin A protein; and
  - b) measuring optical density of the compound, wherein diabetic retinopathy is diagnosed when the measured value represents optical density (ELISA value) lower than normal one.
7. An Immunoglobulin A gene and an analogous gene of SEQ ID NO:3 for coding the protein of claim 1 or 2.

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**